Analysts: Rockwell Medical Inc (RMTI.OQ)
RMTI.OQ on NASDAQ Stock Exchange Global Market
4.98USD
1 Aug 2013
4.98USD
1 Aug 2013
Price Change (% chg)
$-0.07 (-1.39%)
$-0.07 (-1.39%)
Prev Close
$5.05
$5.05
Open
$5.08
$5.08
Day's High
$5.08
$5.08
Day's Low
$4.83
$4.83
Volume
119,940
119,940
Avg. Vol
214,509
214,509
52-wk High
$9.50
$9.50
52-wk Low
$3.16
$3.16
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Buy | -0.24 | December | 2 Aug 2013 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 3 | 3 | 3 | 3 |
| (2) OUTPERFORM | 0 | 0 | 0 | 0 |
| (3) HOLD | 0 | 0 | 0 | 0 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.00 | 1.00 | 1.00 | 1.00 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-13 | 2 | 15.55 | 17.83 | 13.26 | 20.02 |
| Quarter Ending Dec-13 | 2 | 17.75 | 20.17 | 15.34 | 22.82 |
| Year Ending Dec-13 | 2 | 58.91 | 63.92 | 53.90 | 70.34 |
| Year Ending Dec-14 | 3 | 95.08 | 107.17 | 83.40 | 106.69 |
| Earnings (per share) | |||||
| Quarter Ending Sep-13 | 2 | -0.24 | -0.21 | -0.27 | -0.14 |
| Quarter Ending Dec-13 | 2 | -0.19 | -0.17 | -0.22 | -0.07 |
| Year Ending Dec-13 | 2 | -1.30 | -1.25 | -1.36 | -1.01 |
| Year Ending Dec-14 | 3 | -0.32 | -0.09 | -0.68 | -0.14 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Mar-13 | 13.07 | 12.34 | 0.73 | 5.62 |
| Quarter Ending Dec-12 | 13.04 | 13.00 | 0.04 | 0.31 |
| Quarter Ending Sep-12 | 12.69 | 12.69 | 0.00 | 0.02 |
| Quarter Ending Jun-12 | 12.38 | 12.12 | 0.25 | 2.05 |
| Quarter Ending Mar-12 | 11.52 | 12.03 | 0.51 | 4.41 |
| Earnings (per share) | ||||
| Quarter Ending Mar-13 | -0.48 | -0.72 | 0.24 | -48.98 |
| Quarter Ending Dec-12 | -0.66 | -0.66 | 0.00 | -0.50 |
| Quarter Ending Sep-12 | -0.50 | -0.86 | 0.36 | -70.87 |
| Quarter Ending Jun-12 | -0.50 | -0.58 | 0.08 | -16.00 |
| Quarter Ending Mar-12 | -0.57 | -0.54 | 0.03 | -5.26 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-13 | 15.55 | 15.55 | 15.55 | 15.55 | 20.02 |
| Quarter Ending Dec-13 | 17.75 | 17.75 | 17.75 | 17.75 | 22.82 |
| Year Ending Dec-13 | 58.91 | 58.91 | 58.91 | 58.91 | 70.34 |
| Year Ending Dec-14 | 95.08 | 95.08 | 95.08 | 95.08 | 106.69 |
| Earnings (per share) | |||||
| Quarter Ending Sep-13 | -0.24 | -0.24 | -0.24 | -0.24 | -0.14 |
| Quarter Ending Dec-13 | -0.19 | -0.19 | -0.19 | -0.19 | -0.07 |
| Quarter Ending Dec-13 | -1.30 | -1.30 | -1.30 | -1.30 | -1.01 |
| Quarter Ending Dec-14 | -0.32 | -0.32 | -0.32 | -0.32 | -0.14 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Sep-13 | 0 | 0 | 0 | 0 |
| Quarter Ending Dec-13 | 0 | 0 | 0 | 0 |
| Year Ending Dec-13 | 0 | 0 | 0 | 0 |
| Year Ending Dec-14 | 0 | 0 | 0 | 0 |
| Earnings | ||||
| Quarter Ending Sep-13 | 0 | 0 | 0 | 0 |
| Quarter Ending Dec-13 | 0 | 0 | 0 | 0 |
| Year Ending Dec-13 | 0 | 0 | 0 | 0 |
| Year Ending Dec-14 | 0 | 0 | 0 | 0 |
- Rockwell Medical's iron deficiency drug succeeds in trial
- Rockwell Medical's iron deficiency drug succeeds in trial
- Rockwell Medical reports positive data on iron deficiency drug
- UPDATE 1-Rockwell Medical reports positive data on iron deficiency drug
- BRIEF-Rockwell Medical jumps 24 percent in premarket
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Pechala's Reports
|
$25.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Earnings vs.
Estimates